Pulmonary Arterial Hypertension Market to Grow at a CAGR of 3.6% by 2032, Estimates DelveInsight | Merck, Pharmaosa, Mochida, Respira, Gossamer, Insmed, Liquidia Technologies, United Therapeutics

 Breaking News
  • No posts were found

Pulmonary Arterial Hypertension Market to Grow at a CAGR of 3.6% by 2032, Estimates DelveInsight | Merck, Pharmaosa, Mochida, Respira, Gossamer, Insmed, Liquidia Technologies, United Therapeutics

Pulmonary Arterial Hypertension Market to Grow at a CAGR of 3.6% by 2032, Estimates DelveInsight | Merck, Pharmaosa, Mochida, Respira, Gossamer, Insmed, Liquidia Technologies, United Therapeutics
Delveinsight Business Research LLP
The Pulmonary Arterial Hypertension Market size in the seven major markets was approximately USD 4,871.0 million in 2021, which is further expected to increase by 2032. As per DelveInsight, the Pulmonary Arterial Hypertension Market is anticipated to evolve immensely in the coming years owing to the increasing patient population in the 7MM and the launch of new therapies in the market.

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Arterial Hypertension market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pulmonary Arterial Hypertension market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pulmonary Arterial Hypertension: An Overview

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to right ventricular dysfunction and vessel obstruction.

Pulmonary hypertension (PH) is a progressive condition that leads to the narrowing of the arteries of the lungs and heart. It is most common among patients with lung and heart conditions.

Pulmonary Arterial Hypertension Market Key Facts

  • Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension with approximately USD 3,848.1 million in 2021 which is likely to increase by 2032.

  • Among EU4 and the United Kingdom, Germany accounted for approximately USD 211.2 million in 2021, followed by France with approximately USD 169.1 million in the respective year, while Spain accounted for the lowest market with approximately USD 117.0 million in 2021.

  • Japan accounted for approximately USD 243.0 million in 2021, which is expected to increase by 2032.

  • The total prevalent cases of PAH in the 7MM were estimated to be approximately 87,713 cases in 2021, which are expected to increase by 2032.

  • Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021, which is expected to increase further by 2032.

Pulmonary Arterial Hypertension Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pulmonary Arterial Hypertension market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Pulmonary Arterial Hypertension market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pulmonary Arterial Hypertension Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Pulmonary Arterial Hypertension Epidemiology, Segmented as –

  • Total Prevalent Patient Population of PAH in the 7MM [2019–2032]

  • Subtype Specific Prevalence of PAH in the 7MM [2019–2032]

  • Gender-specific Prevalence of PAH in the 7MM [2019–2032]

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to be launched during the study period. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Pulmonary Arterial Hypertension Market Will Evolve and Grow by 2032 @ 


Pulmonary Arterial Hypertension Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Pulmonary Arterial Hypertension. Currently, Liquidia Technologies is leading the therapeutics market with its Pulmonary Arterial Hypertension drug candidates in the most advanced stage of clinical development.

Leading Players in the Pulmonary Arterial Hypertension Therapeutics Market Include

Acceleron Pharma, Aerovate Therapeutics, Altavant Sciences, AstraZeneca, Cereno Scientific, Complexa, Cumberland Pharmaceuticals, Enzyvant Therapeutics, Galectin Therapeutics, Gmax Biopharm Australia, Gossamer Bio, Insmed, Liquida Technologies, Merck, Mezzion, Novartis, Pharmosa BioPharm, PhaseBio Pharmaceutical, Radikal Therapeutics, Respira Therapeutics, Resverlogix, Ribomic, Tenax Therapeutics, United Therapeutics, and others.

Pulmonary Arterial Hypertension Emerging and Marketed Drugs Covered in the Report Include:

  • L606: Pharmaosa Biopharma Inc

  • LIQ861: Liquidia Technologies

  • MK5475: Merck Sharp & Dohme Corp.

  • Ralinepag: United Therapeutics

  • REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceuticals

  • RT234 (vardenafil inhalation powder): Respira Therapeutics

  • Seralutinib (GB002): Gossamer Bio)

  • Sildenafil (Revatio): Pfizer

  • Sotatercept (MK-7962): Merck

  • Treprostinil Palmitil: Insmed Incorporated

  • TYVASO (treprostinil): United Therapeutics

  • UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis

4. Pulmonary Arterial Hypertension Market Overview at a Glance

5. Pulmonary Arterial Hypertension Disease Background and Overview

6. Pulmonary Arterial Hypertension Patient Journey

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Arterial Hypertension Unmet Needs

10. Key Endpoints of Pulmonary Arterial Hypertension Treatment

11. Pulmonary Arterial Hypertension Marketed Products

12. Pulmonary Arterial Hypertension Emerging Drugs and Latest Therapeutic Advances

13. Pulmonary Arterial Hypertension Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Arterial Hypertension Market Outlook (In US, EU5, and Japan)

16. Pulmonary Arterial Hypertension Access and Reimbursement Overview

17. KOL Views on the Pulmonary Arterial Hypertension Market

18. Pulmonary Arterial Hypertension Market Drivers

19. Pulmonary Arterial Hypertension Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Implantable Cardioverter Defibrillators (ICDs) Market

“Implantable Cardioverter Defibrillators (ICDs) Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Implantable Cardioverter Defibrillators market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development in the Implantable Cardioverter Defibrillators Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/